A Phase II Study of Subcutaneously Injected PD-L1 Antibody ASC22 in Chronic Hepatitis B Patients

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2020
The objective of this study is to evaluate the safety and efficacy of ASC22 in the treatment of chronic hepatitis B after single and multiple drug administration.
Epistemonikos ID: 594d3c779f585f4f5ce4e73ec34fce867ea93452
First added on: Nov 24, 2021